| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.088 | 0.03 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.067 | 0.03 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.03 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.068 | 0.03 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |